AKCA Akcea Therapeutics Inc.

14.66
-0.02  -0%
Previous Close 14.68
Open 14.91
Price To Book 2.92
Market Cap 1,488,125,209
Shares 101,509,223
Volume 144,927
Short Ratio
Av. Daily Volume 229,829
Stock charts supplied by TradingView

NewsSee all news

  1. Akcea Announces Appointment of New Chief Financial Officer

    BOSTON, May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice

  2. Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

    BOSTON, May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the

  3. Akcea Therapeutics Canada Confirms Letter of Intent with Pan-Canadian Pharmaceutical Alliance for TEGSEDI™ (inotersen injection)

    For distribution in Canada only                                                                                                 OTTAWA, May 13, 2020 /CNW/ - Akcea Therapeutics Canada, Inc., a subsidiary of Akcea

  4. Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer

    BOSTON, May 7, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president

  5. Akcea Reports Financial Results and Highlights for First Quarter 2020

    BOSTON, May 5, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data met primary endpoint - January 28, 2020.
AKCEA-ANGPTL3-LRx
Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus
Phase 2 data met primary and secondary endpoints - January 22, 2020. Phase 3 trial to be initiated 2020.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
Phase 3 trial has been initiated - noted February 25, 2020.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
CRL issued August 27, 2018. To be refiled 2020.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 3 data met primary endpoint - August 6, 2019.
Volanesorsen
Familial partial lipodystrophy (FPL)
Phase 3 trial initiation announced November 25, 2019.
AKCEA-TTR-LRx
hATTR Amyloidosis
Phase 3 trial initiation announced January 10, 2020.
AKCEA-TTR-LRx - CARDIO-TTRansform
ATTR cardiomyopathy

Latest News

  1. Akcea Announces Appointment of New Chief Financial Officer

    BOSTON, May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice

  2. Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

    BOSTON, May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the

  3. Akcea Therapeutics Canada Confirms Letter of Intent with Pan-Canadian Pharmaceutical Alliance for TEGSEDI™ (inotersen injection)

    For distribution in Canada only                                                                                                 OTTAWA, May 13, 2020 /CNW/ - Akcea Therapeutics Canada, Inc., a subsidiary of Akcea

  4. Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer

    BOSTON, May 7, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president

  5. Akcea Reports Financial Results and Highlights for First Quarter 2020

    BOSTON, May 5, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious

  6. IMPORTANT ALERT: Nationally Ranked Shareholder Rights Firm Labaton Sucharow Announces Proprietary Investigation of Akcea Therapeutics, Inc. (AKCA)

    New York, New York--(Newsfile Corp. - April 29, 2020) - Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf of

  7. Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast

    BOSTON, April 21, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, May 5 at 4:30

  8. Akcea Therapeutics Investor Alert: Investigation on Behalf of Akca Shareholders

    Boston, Massachusetts--(Newsfile Corp. - April 10, 2020) - Thornton Law Firm LLP, a law firm that represents shareholders in recovery actions, is investigating potential breach of fiduciary duty claims on behalf of

  9. Nationally Ranked Shareholder Rights Firm Labaton Sucharow Announces Proprietary Investigation of Akcea Therapeutics, Inc. (AKCA)

    Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf of shareholders of Akcea Therapeutics, Inc.

  10. Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO

    BOSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt,

  11. Akcea Therapeutics Canada celebrates official launch of first-of-its-kind research grant program

    Young Investigator Grant Program Call for Proposals issued to Canadian researchers OTTAWA, March 13, 2020 /CNW/ - Akcea Therapeutics Canada, a subsidiary of Akcea Therapeutics Inc. (NASDAQ:AKCA), congratulates

  12. Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company's leadership team

    BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has joined the company as

  13. Akcea Supports Rare Disease Day 2020 and Global Efforts to "Reframe Rare"

    BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the company's support for Rare Disease Day 2020 and the

  14. Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference

    BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with

  15. Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019

    Reported Full Year 2019 Global Net Product Revenues of $42 Million and Fourth Quarter 2019 Global Net Product Revenues of $14 Million Achieved the 2-2-2 plan: launched two products, initiated two phase 3 programs and

  16. Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast

    BOSTON, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February 25 at

  17. Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx

    Favorable safety and tolerability were observed Primary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3 BOSTON and CARLSBAD,

  18. Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

    BOSTON and CARLSBAD, Calif., Jan. 22, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today announced

  19. Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

    BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced

  20. New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

    Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway

  21. Akcea Retains Rights to AKCEA-APOCIII-LRx

    BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  22. Akcea Therapeutics Announces New Appointments to its Board of Directors

    BOSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointments of Lynne Parshall, J.D., as chair of the

  23. Akcea Announces Appointment of New Chief Operating Officer

    BOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company as chief operating

  24. Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis

    BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  25. Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  26. Akcea Therapeutics to Present at Upcoming Investor Conferences

    BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with

  27. Akcea Reports Financial Results and Highlights for Third Quarter 2019

    Reported Third Quarter 2019 Global Net Product Revenues of $12 Million WAYLIVRA® (volanesorsen) launched in the E.U. Entered into a worldwide licensing agreement with Pfizer, Inc. for AKCEA-ANGPTL3-LRx Conference Call

  28. Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day

    BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today recognizes Familial Chylomicronemia Syndrome (FCS)

  29. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive

  30. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that

  31. Akcea Announces CEO Transition and Elects Two New Board Members

    BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt,

  32. Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

    Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later this year in patients

  33. Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

    Multiple presentations on the long-term efficacy and safety of TEGSEDI® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1 study of